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Severity of local inflammation does 
not impact development of fibrosis 
in mouse models of intestinal 
fibrosis
A. Hünerwadel1, S. Fagagnini1, G. Rogler1, C. Lutz1, S. U. Jaeger2,3, C. Mamie1, B. Weder1, 
P. A. Ruiz1 & M. Hausmann1
Intestinal fibrosis is thought to be a consequence of excessive tissue repair, and constitutes a common 
problem in patients with Crohn’s disease (CD). While fibrosis seems to require inflammation as a 
prerequisite it is unclear whether the severity or persistence of inflammation influences the degree 
of fibrosis. Our aim was to investigate the role of sustained inflammation in fibrogenesis. For the 
initiation of fibrosis in vivo the models of Il10−/− spontaneous colitis, dextran sodium sulfate (DSS)-
induced chronic colitis and heterotopic transplantation were used. In Il10−/− mice, we determined a 
positive correlation between expression of pro-inflammatory factors (Il1β, Tnf, Ifnγ, Mcp1 and Il6). 
We also found a positive correlation between the expression of pro-fibrotic factors (Col3a1 Col1a1, 
Tgfβ and αSma). In contrast, no significant correlation was determined between the expression 
of pro-inflammatory Tnf and pro-fibrotic αSma, Col1a1, Col3a1, collagen layer thickness and the 
hydroxyproline (HYP) content. Results from the DSS-induced chronic colitis model confirmed this 
finding. In the transplantation model for intestinal fibrosis a pronounced increase in Mcp1, inos and 
Il6 in Il10−/− as compared to WT grafts was observed, indicating more severe inflammation in Il10−/− 
grafts. However, the increase of collagen over time was virtually identical in both Il10−/− and WT grafts. 
Severity of inflammation during onset of fibrogenesis did not correlate with collagen deposition. 
Although inflammation might be a pre-requisite for the initiation of fibrosis our data suggest that it 
has a minor impact on the progression of fibrosis. Our results suggest that development of fibrosis 
and inflammation may be disconnected. This may be important for explaining the inefficacy of anti-
inflammatory treatments agents in most cases of fibrotic inflammatory bowel diseases (IBD).
IBD, with its two entities CD and ulcerative colitis (UC), are chronic auto-inflammatory disorders with a poly-
genic background and multiple environmental triggers1. In the pathogenesis of IBD, inflammation is sustained 
by an exaggerated response of T-lymphocytes2 associated with an infiltrate of immune cells, which may cause 
severe local tissue damage3. In CD patients, the inflammation has been associated with an excessive T helper type 
1 (TH1) and T helper type 17 (TH17) response with massive production of pro-inflammatory cytokines such as 
interleukin (IL)-1, -2, -6, -12 and interferon (IFN)-γ – at least in mouse models4,5.
In the intestinal mucosa, severe inflammation is followed by loss of epithelial cells and the degradation of 
collagen-rich extracellular matrix (ECM) in the lamina propria, leading to ulcerations. This, in turn, leads to the 
initiation of a reparatory process, as rapid and adequate healing is essential to restore a tight barrier and reduce 
the exposure of the underlying tissue to luminal antigens3,6,7. Excessive ECM deposition impairs gastrointestinal 
function due to motility abnormalities and increased wall stiffness, and promotes fibrosis, which is increasingly 
recognised as an important cause of morbidity and mortality in IBD. CD has a fibrostenosis phenotype at diag-
nosis in at least 10% of patients8–10, constituting a common clinical problem. Intestinal fibrosis leads to stricture 
formation in 30–50% of patients with CD9,11, and requires surgery in approximately 80% of these patients9. UC 
has been long considered a non-fibrotic disease, but some degree of submucosal fibrosis is found in almost all 
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of colectomy specimens from patients with UC8,12,13, and the degree of fibrosis is proportional to the degree of 
chronic but not active inflammation13.
It is evident from clinical observations that fibrosis only develops in segments of the gut where inflammation 
is or was present8. Fibrosis occurring in gut segments that never showed signs of inflammation has not been 
reported. Nevertheless, the exact factors and mechanisms triggering fibrosis remain unclear. While fibrosis seems 
to require inflammation as a prerequisite, the mechanisms involved in the progression of fibrogenesis may be dis-
tinct and idependent of the degree of inflammation. There is evidence that intestinal fibrogenesis - once initiated 
– may become an independent and “self-perpetuating” process14.
Based on data from experiments with bleomycin (BLM) induced fibroinflammatory responses in murine 
lung, the association between inflammation and fibrosis is discussed since decades15–17, as pulmonary fibrosis was 
suggested to be independent from preceding inflammation.
IL-10 is considered to be one of the most important anti-inflammatory cytokines in humans, produced 
by various cells of the innate and adaptive immune system such as CD4+ T-cells, CD8+ T-cells, macrophages, 
dendritic cells (DC) and mast cells4. IL-10 initiates a negative regulatory pathway triggered by the production 
of pro-inflammatory cytokines4,18. IL-10 binding to its receptor (IL-10R) leads to phosphorylation, dimeri-
zation and nuclear translocation of STAT3. This leads to an increase in anti-inflammatory and a decrease in 
pro-inflammatory cytokine expression4,19 and MHC-II class molecule expression in DC and macrophages4,18. 
Together with its participation in a negative feedback loop circuit, IL-10 also plays a crucial role in the con-
trol of inflammation via CD4+CD25+ regulatory T cells (Tregs). CD4+CD25+ Tregs cells produce and require 
IL-10 to suppress TH1 and TH17 to control and terminate the immune response20. Due to their ability to conduct 
self-tolerance and establish an immune homeostasis, Tregs play a crucial role in the orchestration of immune 
responses21. Tregs mainly act via the inhibition of function, proliferation and cytokine production of other 
immune cells21.
Mutations in IL-10 and IL-10R are associated with a severe course of IBD19,22,23. Genetic variants of IL-10 in 
humans are associated with increased susceptibility to UC24. In CD patients, mutations in IL-10 protein reduce its 
release from cells25, and a mutation (3020insC) in the intracellular sensor molecule nucleotide-binding oligomer-
ization domain containing 2 (NOD2), previously associated with CD, inhibits the ribonucleoprotein hnRNP-A1, 
and thereby actively blocks transcription of IL-1019,26. However, there are no data on the direct role of IL-10 and 
IL-10R in the pathomechanism of intestinal fibrosis. Nevertheless, IL-10 is known to decrease tissue remodeling 
protease matrix metalloproteinase (Mmp)9 at a transcriptional level. MMP9 is a endopeptidase responsible for 
the degradation of denatured collagens and basement membranes27 causing further tissue damage and inflam-
mation28,29. MMP9 is also involved in many developmental processes, including wound healing and ECM degra-
dation, cell migration and invasion. Recent data indicate that MMP9 plays a role in the modulation of intestinal 
fibrosis, and suggest that selective MMP9 inhibition is a promising therapeutic strategy for treatment of pene-
trating CD30.
Our aim was to investigate the role of sustained intestinal inflammation on fibrogenesis, and whether 
increased inflammation correlates with an increase in fibrotic processes. In this study, we describe the impact 
of inflammation on fibrogenic processes using three different models of intestinal fibrosis. Our data suggest that 
inflammation might be a pre-requisite for the initiation of fibrosis but has only a minor or no impact on the pro-
gression of fibrosis. This finding may help to explain the little impact most anti-inflammatory treatments have on 
IBD-associated fibrosis.
Materials and Methods
Animals. Chronic colitis was induced as described previously31. Mice weighing 20 g on average were bred 
locally in the animal facility of the University Hospital Zurich. The animals received standard laboratory mouse 
food and water ad libitum. They were housed under specific pathogen-free conditions in individually ventilated 
cages. During a cycle of chronic colitis mice received either 1.75% dextran sodium sulfate (DSS) in drinking 
water or drinking water alone over seven days. DSS was administred in a total of 3 cycles with 14 days of recovery 
between each cycle. Three weeks after the last DSS administration cycle the mice were euthanized.
For the model of spontaneous colitis Il10−/− mice (C57BL/6) were used. Mice were observed until they 
reached 11–20 weeks of age. For the heterotopic transplantation model, male B.6129P2IL-10tm1Cgn/J (IL-10−/−) 
and C57BL/6-Tg (UBC-green fluorescence protein [GFP] 30Scha/J, WT) were used. Surgeries were always per-
formed during the light cycle. The use of C57BL/6-Tg allows to determine the origin of lumen-obstructing cells or 
the progression of lymphocyte influx. We did not apply this option in this work, hence C57BL/6-Tg are referred 
as WT in the following text.
Heterotopic intestinal transplant model. The heterotopic mouse intestinal transplant model is an adap-
tion of the heterotopic transplantation model of intestinal fibrosis in rats, which has been previously described 
in detail32. Briefly, donor small bowel resections were extracted and transplanted subcutaneously into the neck of 
recipient animals. Donor small bowel proximal to the caecum was excised and flushed with 5 ml of 0.9% NaCl to 
remove stool, and divided into 10 mm parts. A small bowel resection was implanted into a subcutaneous pouch, 
and a single dose of cefazolin (Kefzol®, 1 g diluted in 2.5 ml aqua dist.) was applied i.p. as infection prophylaxis.
IL-10−/− and WT mice were used as both donors and recipients for isogeneic transplantation. Body weight 
remained unchanged. 112 transplants were performed and all but 5 grafts were recovered. Grafts were explanted 
up to 21 days after transplantation. To compare grafts with non-transplanted tissue, 21 small bowel resections 
were extracted from IL-10−/− mice and 19 small bowel resections were extracted from WT mice.
qPCR. qPCR was performed using Taqman gene expression assays for Il1β Mm01336189_m1, 
inos Mm01309893_m1, Mcp1 Mm00441242_m1, Ifnγ Mm00439552_s1, Mmp-9 Mm00442991_m1, 
www.nature.com/scientificreports/
3SCIenTIFIC RePoRtS |  (2018) 8:15182  | DOI:10.1038/s41598-018-33452-5
Timp-1 Mm00441818_m1, Loxl-2 Mm00804740_m1, Col1a1 Mm00801666_g1 and Gapdh 4352339E. Relative 
gene expression was calculated using the ΔΔCt-method.
Collagen layer thickness measurement. Samples were processed using a benchtop tissue processor 
(Leica TP 1020) prior to be embedded and cut into 5 µm sections. To visualize the collagen layer, the samples were 
stained with Sirius Red according to a standard protocol33. Sirius red staining was examined using the Imager Z2 
microscope (Zeiss) and the software AxioVision (Zeiss). Quantification of the Sirius red-stained collagen was 
performed by ImageJ 1.47t (NIH, USA) using pictures taken under transmission light, as well as a polarized light 
filter. Collagen layer thickness was determined in 5 μm sections by a blinded investigator from at least eight places 
in representative areas at 10-fold magnification. Sirius Red-stained slides were analyzed by bright-field micros-
copy with an additional polarizing filter. Under polarized light, Sirius Red-stained collagen assumes a palette of 
colors ranging from green to red based on the fibrotic maturation process. Elastica van Gieson-stained slides were 
analyzed by transmission light microscopy.
Statistical analysis. Statistical analysis for qPCR and collagen layer thickness was performed using 
Kruskal-Wallis one way analysis of variance on ranks, all pairwise multiple comparison procedures, Dunn’s 
method. Comparison between genotypes was performed using the Mann-Whitney-Test for each time point. 
Differences were considered significant at a p-value of < 0.05 (*) and highly significant at a p-value of < 0.01 (**) 
and p-value of < 0.001 (***).
Ethical considerations. The experimental protocol for animals was approved by the local Animal Care 
Committee of the University of Zurich (registration numbers 114/2011 and ZH183/2014). We herewith confirm 
that all experiments were performed in accordance with relevant guidelines and regulations.
Results
Fibrogenesis is not affected by inflammatory gene expression levels in the murine model of 
spontaneous colitis. We hypothesized that the level of inflammation plays a minor role in fibrosis formation 
in murine intestine. Three different murine models were used. At first, the Il10−/− model of spontaneous colitis 
was applied. Il10−/− mice showed a significantly increased MPO and histological score in the intestinal mucosa 
compared to WT in both small bowel and colon (Fig. 1A,B). This is reflected by an increased lymphocyte influx 
into the mucosa (Fig. 1B). Regarding fibrosis parameters, Il10−/− mice showed a significantly increased collagen 
Figure 1. Inflammation is a pre-requisite for the initiation of fibrosis in the spontaneous colitis model. (A) 
MPO. (B) Histological score. (C) Collagen layer thickness from small bowel and colon. Mann-Whitney 
rank sum test each. (D) Significant link between collagen layer thickness from the small bowel and the colon 
(Pearson product moment correlation).
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layer thickness compared to WT in both the small bowel and the colon (Fig. 1C). We found a correlation between 
the collagen layer thickness of the small bowel and the colon (Fig. 1D).
In the small bowel from Il10−/− mice, we determined a positive correlation between pro-inflammatory factors. 
Il1β is similarly regulated to Tnf, Ifnγ, Mcp1 and Il6 (Fig. 2A and Table 1, cytokines were assigned to pro-fibrotic 
or anti-fibrotic function according to Rieder et al.34). In addition, we determined a positive correlation between 
pro-fibrotic factors. Col3a1 is similarly regulated to Col1a1, Tgfβ and αSma (Fig. 2B and Table 1). In contrast, no 
significant correlation was determined between pro-inflammatory Tnf and pro-fibrotic αSma, Col1a1, Col3a1, 
Figure 2. No correlation between pro-inflammatory and pro-fibrotic parameters in the spontaneous colitis 
model. qPCR from small bowel whole tissue, and collagen layer thickness measurement from the small bowel. 
(A) Pro-inflammatory factors. (B) Pro-fibrotic factors. (C) Pro-inflammatory parameters do not correlate with 
pro-fibrotic parameters (Pearson product moment correlation each, nonlinear regression shown if p < 0.05).
pro-fibrotic anti-fibrotic
pro-inflammatory
αSma Col1a1 Col3a1 Tgfβ Mcp1 Il1β Tnf Ifnγ
pro-fibrotic pro-inflammatory
αSma 0.0176 0.00452 NS 0.00279 0.007 NS NS
Col1a1 0.0176 0.0138 NS 0.0129 NS NS NS
Col3a1 0.00452 0.0138 0.0000518 0.0081 0.00671 NS NS
Tgfβ NS NS 0.0000518 NS NS 0.00239 NS
Mcp1 0.00279 0.0129 0.0081 NS 0.00524 0.0158 NS
Il1β 0.007 NS 0.00671 NS 0.00524 0.000049 0.00556
Tnf NS NS NS 0.00239 0.0158 0.000049 NS (0.0861)
anti fibrotic Ifnγ NS NS NS NS NS 0.00556 NS (0.0861)
Table 1. No significant correlation between pro-inflammatory Tnf and pro-fibrotic markers. qPCR from small 
bowel whole tissue sections. Pearson product moment correlation. Tgfβ, Mcp1, Il1β and Ifnγ were assigned to 
pro-fibrotic or anti-fibrotic function according to Rieder et al.34.
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and collagen layer thickness (Fig. 2C and Table 1). In addition, no significant correlation was determined between 
the HYP content and the expression levels of pro-inflammatory markers. Likewise, no significant correlation was 
determined between pro-fibrotic Col1a1 and pro-inflammatory Tnf, Il1β, Ifnγ, Il6 or MPO (Fig. 2C and Table 1). 
During spontaneous colitis, changes in inflammatory expression were not reflected by changes in fibrosis associ-
ated gene expression. Tgfβ, which has a dual function sharing pro-inflammatory and pro-fibrotic features, cor-
related with pro-inflammatory Tnf (Fig. 3). qPCR data from colon whole tissue confirmed the results from small 
bowel (Supplementary Fig. 1).
Fibrogenesis is not affected by inflammatory gene expression levels in the DSS-induced 
model of chronic colitis. As a second experimental approach we used the DSS-induced chronic colitis 
model. Regarding inflammatory parameters, mice suffering from chronic colitis showed a significantly increased 
MEICS compared to WT (Fig. 4A). Mice suffering from chronic colitis showed a significantly increased MPO 
(Fig. 4B) and histological score in the colon samples (Fig. 4C). This is reflected by an increased lymphocyte influx. 
Mice suffering from chronic colitis showed a significantly increased collagen layer thickness compared to WT 
(Fig. 4D). Pro-inflammatory Tnf, Ifnγ, Il6 and Il1β mRNA expression levels were increased in colitis (Fig. 4E).
In the colon from mice suffering from DSS-induced chronic colitis, we determined a positive correlation 
between pro-inflammatory factors. Il1β is similarly regulated to Tnf and Il6 (Fig. 5A). In addition, we deter-
mined a positive correlation between pro-fibrotic factors. Col3a1 is similarly regulated to Col1a1, Tgfβ and αSma 
(Fig. 5B). In contrast, no significant correlation was determined between pro-inflammatory Tnf and pro-fibrotic 
Col3a1, and collagen layer thickness (Fig. 5C). During DSS-induced chronic colitis, changes in inflammatory 
expression were not reflected by fibrosis associated gene expression. Tgfβ, which exhibits pro-inflammatory and 
pro-fibrotic features, showed a trend towards a significant correlation to pro-inflammatory Tnf (Fig. 6).
Fibrotic gene expression is not affected by inflammation in the heterotopic transplantation 
model. In a third experimental approach we performed transplantation of the intestine according to the het-
erotopic animal model for intestinal fibrosis. For this purpose small bowel resections from both non-inflamed 
WT and inflamed IL-10 deficient mice were used. IL-10 is a potent macrophage-deactivating cytokine, which is 
associated with the suppression of IFNγ and iNOS expression.
Control tissue was obtained from Il10−/− and WT mice. Here, mRNA expression of Mcp1, Ifnγ, inos, Il18 and 
Il6. Mcp1, inos and Il6 was significantly increased in freshly isolated resections from Il10−/− compared to WT 
mice (Fig. 7A). Ifnγ and Il18 expression further confirmed increased inflammation in Il10−/− mice compared to 
WT mice. Both small bowel and colon showed massive lymphocyte influx into the mucosa in inflamed Il10−/− 
mice compared to non-inflamed WT mice (Fig. 7B).
Following the initiation of fibrosis by heterotopic transplantation, we investigated whether increased inflam-
mation in the absence of IL-10 has an effect on fibrotic processes. 7 days after transplantation, Col1a1 mRNA 
expression was significantly increased in grafts from Il10−/− donors transplanted into Il10−/− recipients compared 
to freshly isolated small bowel from Il10−/− mice (Fig. 7C, 98.3 ± 149.6 vs. 1.0 ± 0.7, respectively, n = as indicated, 
p < 0.05*). In comparison to grafts from IL-10−/−, Col1a1 expression in grafts from WT donors transplanted 
into WT recipients appeared to be delayed on day 7 (Fig. 7C, 98.3 ± 149.6 vs. 24.8 ± 21.9, respectively). However, 
fibrosis was further increased 14 and 21 days after transplantation in a time-dependent manner in grafts from 
both Il10−/− and WT donors showing similar values.
Lysyl oxidase homolog (LOXL) catalyses the first step in the formation of crosslinks in collagens and elastin. 
Loxl mRNA expression in grafts from WT donors appeared to be delayed on day 7 compared to grafts from 
Il10−/− mice (Fig. 7D, 12.2 ± 15.9 vs. 2.2 ± 1.2, respectively). Loxl expression was further increased 14 days after 
Figure 3. Tgfβ, which shares pro-inflammatory and pro-fibrotic features, correlates with pro-inflammatory 
Tnf. qPCR from small bowel whole tissue from mice suffering from spontaneous colitis (Pearson product 
moment correlation nonlinear regression).
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transplantation in grafts from both Il10−/− and WT donors showing similar values (Fig. 7D, 61.9 ± 23.4 vs. 
50.0 ± 28.1, respectively). Although Loxl expression was significantly increased in grafts compared to freshly iso-
lated small bowel (day 0, Fig. 7D, *p < 0.05) no difference could be determined between grafts from Il10−/− and 
WT donors suggesting that preceding inflammation of resections has no effect on fibrogenesis.
As genes responsible for assembly of collagen during fibrogenesis were increased in fibrogenesis in a time 
dependent manner irrespectively of the presence of IL-10, we next determined the expression of matrix metal-
loproteinase (Mmp9) and its natural inhibitor tissue inhibitor of metalloproteinase (Timp)1, which is also rele-
vant for disassembly of collagen. Grafts isolated from both Il10−/− and WT recipient mice showed a decrease in 
Mmp9/Timp1 ratio when compared to freshly isolated small bowel. Ratios from both Il10−/− and WT recipients 
showed similar values (Fig. 7E).
Collagen deposition during fibrogenesis is independent of preceding inflammation. Next, we 
determined collagen deposition after heterotopic transplantation in histological cross sections of grafts from 
Il10−/− and WT donors using Sirius red staining under transmission light microscopy (Fig. 8). Freshly isolated 
small intestine was characterized by an open lumen and distinctive epithelial crypts (Fig. 8A,B). At day 7 after 
transplantation, the lumen of intestinal grafts was obstructed by granulation tissue and fibrotic material (Fig. 8C–
F). Polarizing light microscopy revealed collagen adjacent to the submucosa in freshly isolated small intestine 
(Fig. 8G,H). In contrast, collagen deposition was increased in the submucosa and in the luminal occlusion fol-
lowing transplantation (Fig. 8I–L). Collagen layer thickness in harvested grafts was significantly increased in 
comparison to freshly isolated small intestine irrespective of the genotype of donor and recipient mice (Fig. 8M, 
p < 0.001***), indicating that collagen deposition was unrelated to preceding inflammation. Loss of epithelial 
structures and luminal occlusion was observed in grafts from both IL-10−/− and WT donors. An increase in col-
lagen deposition independent of preceding inflammation of the grafts was also confirmed by Elastica van Gieson 
(EvG) staining (Supplementary Fig. 2).
The expression of pro-inflammatory Il1β does not correlate with collagen layer thickness in 
the heterotopic transplant model. Pre-existing intestinal inflammation could have an impact on the 
severity of inflammatory processes during fibrogenesis. Therefore, we next aimed to determine the severity of 
inflammation during fibrogenesis in both WT and IL-10−/− mice. Il1β expression in grafts was increased 7 days 
after transplantation compared to freshly isolated small bowel, but grafts of both WT and IL-10−/− donors showed 
similar values during fibrogenesis (Fig. 9A, 65.4 ± 46.2 and 28.8 ± 8.3 compared to 1.0 ± 0.19 and 1.0 ± 0.26, 
respectively). IL-10−/− mice develop a chronic colitis after 12–15 weeks that worsens in an age-dependent man-
ner. Therefore, we next analyzed whether mRNA expression of Il1β depends on the age of donors. Il1β mRNA 
expression was increased in grafts from three months old IL-10−/−−/− donors transplanted into IL-10−/− recipi-
ents compared to freshly isolated small bowel from IL-10−/− mice (Fig. 9B, 27.7 ± 14.6 vs. 1.7 ± 0.3, respectively), 
Figure 4. Inflammation is a pre-requisite for the initiation of fibrosis in DSS-induced chronic colitis. (A) 
MEICS. (B) MPO. (C) Histological score. (D) Collagen layer thickness from colon. (E) qPCR. Mann-Whitney 
rank sum test each.
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and was significantly increased in grafts from both four and five months old IL-10−/− donors compared to freshly 
isolated small bowel (Fig. 9B, p < 0.05*). However, Il1β mRNA expression was not correlated to collagen layer 
thickness of grafts (Fig. 9C). Moreover, the collagen layer thickness in harvested grafts was not increased in an age 
Figure 5. No correlation between pro-inflammatory and pro-fibrotic parameters in DSS-induced chronic 
colitis. qPCR from colon whole tissue and collagen layer thickness measurement from colon. (A) Pro-
inflammatory factors. (B) Pro-fibrotic factors. (C) Pro-inflammatory parameters do not correlate with pro-
fibrotic parameters (Pearson product moment correlation each, nonlinear regression shown if p < 0.05).
Figure 6. Tgfβ, which shares pro-inflammatory and pro-fibrotic features, correlates with pro-inflammatory 
Tnf. qPCR from colon whole tissue from mice suffering from DSS-induced chronic colitis (Pearson product 
moment correlation nonlinear regression).
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dependent manner (Supplementary Fig. 3), suggesting no correlation of fibrogenesis to the inflammatory status 
of the donor.
Further, grafts of Il10−/− donors showed increased levels of Ifnγ, Il18 and Il6 mRNA expression compared to 
WT (Fig. 10A–C,E), but mRNA expression was not correlated to collagen layer thickness of grafts (Fig. 10B–D,F).
Discussion
In this study we investigated how the severity of inflammation affects the development and extent of intestinal 
fibrosis in three different mouse models. Both the Il10−/− mouse model and the DSS-induced model of chronic 
colitis have been proposed as appropriate for investigating intestinal fibrosis because in the chronic phase, an 
accumulation of ECM is detectable in the affected intestine. In both, the Il10−/− model of spontaneous colitis and 
the DSS-induced model of chronic colitis, fibrosis developed following intestinal inflammation. This is similar to 
the clinical observation that fibrosis only develops in gut segments where inflammation is or was present8. Model 
specific progressions of the inflammatory status, like the increased expression of pro-inflammatory mRNAs and 
the increase in MPO, were associated with increased expression of pro-fibrotic mRNAs, deposition of ECM and 
thickening of the bowel wall. However, pro-inflammatory markers were not correlated to fibrosis associated 
markers in a significant manner. Deposition of ECM and activation of fibroblasts could be uncoupled from the 
degree of inflammation in the course of fibrogenesis.
Furthermore, we investigated the link between the severity of the inflammation and the lack of IL-10 on the 
development of fibrosis using the heterotopic transplantation model. To study the potential impact of the severity 
of inflammation we studied IL-10 deficient animals as donors and recipients of the graft. Anti-inflammatory 
IL-10 is a potent macrophage-deactivating cytokine35,36 and a suppressor of iNOS expression37,38. Conversely, 
IL-10 depletion results in an increase of IFNγ in colonic mucosa39. Although determined pronounced differ-
ences in the expression of these cytokines and mediators between IL-10−/− and WT animals, as well as a massive 
influx of lymphocytes in the mucosa of IL-10−/−, the development of intestinal fibrosis was not influenced by the 
IL-10 deficiency. A very similar development of fibrosis was found in grafts from both IL-10−/− and WT donors. 
Collagen expression and deposition, which increased over time, was virtually identical in both IL-10−/− and WT 
grafts after 14 and 21 days. Increased collagen deposition in the intestinal wall was determined by histological 
Figure 7. Induction of Col1a1 and Loxl mRNA expression during fibrosis reach the same level in grafts from 
Il10−/− and WT donors in the transplant model of fibrosis. (A) qPCR confirmed increase of Mcp1, Ifnγ, inos, 
Il18 and Il6 in the small bowel from Il10−/− donor mice compared to WT (*p < 0.05). (B) H&E. Lymphocyte 
influx is increased in small bowel and colon of Il10−/− compared to WT. (C) Col1a1 mRNA expression is 
significantly increased in grafts from Il10−/− donor mice transplanted into Il10−/− recipients at day seven 
compared to freshly isolated intestine from Il10−/−. (D) Loxl mRNA expression is significantly increased in 
grafts from both Il10−/− donor mice transplanted into Il10−/− recipients and WT donor mice transplanted 
into WT recipients from day 14 compared to freshly isolated intestine and grafts from day 7. (E) Mmp9/Timp1 
ratio is decreased in grafts from day 7 compared to freshly isolated intestine independent from the genotype 
(*p < 0.05, n = as indicated).
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Figure 8. Development of intestinal fibrosis is not prevented in grafts from Il10−/− donors in the transplant 
model of fibrosis. Sirius red staining. Transmission light showed the collagen layer in freshly isolated grafts from 
(A) WT and (B) IL-10−/− mice in comparison to an increased collagen layer thickness in grafts at day seven 
from WT donor mice transplanted into (C) WT and (D) IL-10−/− recipients next to grafts from IL-10−/− donors 
transplanted into (E) WT and (F) IL-10−/− recipients. (G,H,I–L) Polarized light. (M) Collagen layer thickness 
increased significantly in grafts following transplantation. Kruskal-Wallis One Way Analysis of Variance on 
Ranks, All Pairwise Multiple Comparison Procedures (Dunn’s Method), mean value, SD (*** p < 0.001).
Figure 9. Il1β expression does not correlate with collagen layer thickness in the transplant model of fibrosis. (A) 
Il1β is increased in grafts from both IL-10−/− donor mice transplanted into IL-10−/− recipients and WT donor 
mice transplanted into WT recipients from day 7 compared to freshly isolated intestine. (B) qPCR confirmed that 
Il1β mRNA expression is significantly increased in grafts from IL-10−/− donor mice four and five months of age 
transplanted into Il10−/− recipients at day 7 compared to freshly isolated intestine from Il10−/− (*p < 0.05, n = as 
indicated). (C) Il1β does not correlate with collagen layer thickness (Pearson correlation p > 0.050).
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analysis, and confirmed the qPCR data. EvG and Sirius red staining demonstrated an identical network of colla-
gen fibrils accumulating progressively in grafts from both genotypes. Expression of genes responsible for assem-
bly of ECM in fibrogenesis, as well as collagen deposition in intestinal grafts showed similar values regardless of 
the gentic background of donors and recipient and the lack or presence of IL-10. Therefore, we assume that the 
severity of inflammation during fibrogenesis does not correlate with collagen deposition.
Several animal models for the study of intestinal fibrosis have been proposed8. All of them have some advan-
tages as well as disadvantages and none of them really resembles intestinal fibrosis of CD patients. The transplant 
model of intestinal fibrosis is also an artificial model and therefore may have its own limitations. The exact cause 
for the initiation and progression of fibrosis in the heterotopic intestinal transplant model is unknown. Graft 
rejection, ischemia, hypoxia, increased Hif1α and neo-vascularisation could contribute to fibrosis in this animal 
model32,40. An excessive synthesis of ECM and activation of intestinal myofibroblasts positive for both vimentin 
and αSMA, hallmarks in the development of fibrosis, are detectable in the heterotopic transplant animal model of 
intestinal fibrosis32,41. Additionally, IL-13, a known inducer of TGFβ expression, is significantly increased in grafts 
in a time-dependent manner32. The immune response to grafts most probably is strain specific. Previously, we 
observed an increase in neutrophils in the heterotopic transplantation model that may be affected by the immune 
response to intestinal grafts, rejection, ischemia or hypoxia, which contributes to fibrosis in the animal model but 
Figure 10. Ifnγ, Il18 and Il6 expression do not correlate with collagen layer thickness in the transplant model 
of fibrosis. (A) Anti-fibrotic Ifnγ is significantly increased in grafts from Il10−/− donor mice transplanted into 
Il10−/− recipients from day 7 compared to WT. (B) Ifnγ does not correlate with collagen layer thickness. (C) 
Pro-inflammatory Il18 and (E) Il6 is significantly increased in Il10−/− compared to WT. (D) Il18 and (F) Il6 do 
not correlate with collagen layer thickness (Mann-Whitney rank sum test as indicated and Pearson correlation 
p > 0.050 each).
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not necessarily to fibrosis in IBD patients40. Differences in the microbiome are likely to influence the development 
of intestinal fibrosis.
There is already mounting evidence that intestinal fibrogenesis once initiated is no longer depending on the 
presence of inflammation14. For example, in the S. typhimurium colitis model very early antibiotic intervention 
with levofloxacin repressed bacteria-induced inflammation and subsequent fibrosis. Late eradication of bacte-
ria did not alter the development of intestinal fibrosis, suggesting that fibrosis is self-propagative. Furthermore, 
pulmonary fibrosis experiments in mice treated with BLM intratracheally indicate that fibrosis could develop 
independently from preceding inflammation. Further, fibrosis could be induced in C57BL/6 SCID mice lack-
ing mature T and B cells, suggesting that lymphocytes are not required for the induction of the disease17,42. 
IL-12p40−/− mice lacking a p70 cytokine to promote T-helper-1-mediated inflammation showed less inflam-
mation upon BLM compared to WT, whereas pulmonary fibrosis and hydroxyproline content were increased 
in IL-12p40−/− mice16. The pro-fibrotic cytokine IL-6, capable of fibroblast activation and promotion of col-
lagen synthesis, was found to be substantially increased in IL-12p40−/− mice, and was suggested to promote 
BLM-mediated lung fibrosis.
The importance of IL-10-dependent signalling is well established, as well as the impact of IL-10 deficiency 
in the initiation of inflammation in different animal models and diseases. Nonetheless, the exact role of IL-10 
in the subsequent development of fibrosis remains unclear and is subject of some discussion. In BLM-mediated 
injury, pulmonary inflammation was promoted in IL-10−/− mice, as reflected by an increased representation of 
lymphocytes compared to WT15, but no difference was found in the degree of pulmonary fibrosis, as evidenced by 
histology and hydroxyproline content. These studies suggest an immunomodulary role for IL-10−/− in the inflam-
matory response but not in BLM-induced pulmonary fibrosis and are in line with our findings in the heterotopic 
transplant model of small intestinal fibrosis.
On the other hand, there is evidence from many different animal models that lack of IL-10 may lead to fibro-
sis, and administration of IL-10 is followed by decreased fibrosis. However, studies on the distinction between 
the role of IL-10 in the initiation of inflammatory processes and the development of fibrosis are limited. Recent 
data show that IL-10 may display anti-fibrotic effects during unilateral ureteral obstruction through surgical 
ligation43. Histological analysis showed an increased rate of tubular injury in IL-10 deficient mice. Collagen dep-
osition and activation of myofibroblasts were also increased compared to WT mice. Interestingly, the expression 
pro-inflammatory IL-6 was increased in IL-10 deficient mice, suggesting a crucial role for IL-10-induced IL-6 
in the protection from renal fibrosis. In a model of granulomatous experimental thyroiditis, lack of IL-10 led 
to ongoing inflammation and fibrosis associated with the destruction of thyroid follicles. In this model, IL-10 is 
required to activate FasL on T cells initiating apoptosis44, therefore, the absence of IL-10 increases the lifespan of 
activated lymphocytes and maintains inflammation. In a model of cerulean-induced acute pancreatitis, a severe 
increase of fibrosis was observed in IL-10 knockout mice compared to WT45, together with increased TGF-β1 
plasma levels in pancreatic cells. Histological evaluation of collagen deposition in the pancreas of IL-10 deficient 
mice confirmed increased fibrogenesis compared to WT. Recently, Mentink-Kane et al. also demonstrated the 
anti-fibrotic properties of IL-10 in a pathogen driven inflammation model of the liver46. These authors showed 
that IL-10, IL-12p40 and IL-13Ralpha act cooperatively through reduction of pro-fibrotic IL-13. A positive effect 
of treatment with recombinant IL-10 was shown in a rat model with CCL4 induced hepatic fibrosis47. Upon 
administration of recombinant IL-10 animals showed a decreased collagen deposition in the fibrotic liver.
Our data suggest that, although IL-10 reduces inflammation, fibrogenesis is uncoupled from IL-10 signal-
ling. The degree of inflammation and the expression levels of pro-inflammatory cytokines had no impact on the 
development of fibrosis in our model. From a clinical perspective, current anti-inflammatory agents effectively 
treat inflammatory flares in IBD patients, but at present, there is no specific treatment option for patients with 
recurrent intestinal fibrosis48,49. In consequence, the incidence of strictures and subsequent surgical interventions 
remains relatively unchanged50. Treatment avenues outside the classical anti-inflammatory approaches might end 
up more promising.
References
 1. Rogler, G., Zeitz, J. & Biedermann, L. The Search for Causative Environmental Factors in Inflammatory Bowel Disease. Digestive 
diseases (Basel, Switzerland) 34(Suppl 1), 48–55, https://doi.org/10.1159/000447283 (2016).
 2. Ina, K. et al. Resistance of Crohn’s disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. 
Journal of immunology (Baltimore, Md.: 1950) 163, 1081–1090, doi:ji_v163n2p1081 [pii] (1999).
 3. Rieder, F., Brenmoehl, J., Leeb, S., Scholmerich, J. & Rogler, G. Wound healing and fibrosis in intestinal disease. Gut 56, 130–139, 
https://doi.org/10.1136/gut.2006.090456 (2007).
 4. Paul, G., Khare, V. & Gasche, C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 42, 95–109, https://doi.
org/10.1111/j.1365-2362.2011.02552.x (2012).
 5. Murai, M. et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive 
function in mice with colitis. Nat Immunol 10, 1178–1184, https://doi.org/10.1038/ni.1791 (2009).
 6. Jones, M. K., Tomikawa, M., Mohajer, B. & Tarnawski, A. S. Gastrointestinal mucosal regeneration: role of growth factors. Frontiers 
in bioscience: a journal and virtual library 4, D303–309 (1999).
 7. Sartor, R. B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterology clinics of 
North America 24, 475–507 (1995).
 8. Rieder, F., Fiocchi, C. & Rogler, G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel 
Diseases. Gastroenterology 152, 340–350–e346, https://doi.org/10.1053/j.gastro.2016.09.047 (2017).
 9. Cosnes, J. et al. Long-term evolution of disease behavior of Crohn’s disease. Inflammatory bowel diseases 8, 244–250 (2002).
 10. Louis, E. et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. 
Gut 49, 777–782 (2001).
 11. Freeman, H. J. Natural history and clinical behavior of Crohn’s disease extending beyond two decades. Journal of clinical 
gastroenterology 37, 216–219 (2003).
 12. Gordon, I. O., Agrawal, N., Goldblum, J. R., Fiocchi, C. & Rieder, F. Fibrosis in ulcerative colitis: mechanisms, features, and 
consequences of a neglected problem. Inflammatory bowel diseases 20, 2198–2206, https://doi.org/10.1097/mib.0000000000000080 
(2014).
www.nature.com/scientificreports/
1 2SCIenTIFIC RePoRtS |  (2018) 8:15182  | DOI:10.1038/s41598-018-33452-5
 13. Agrawal, N. et al. In Ulcerative Colitis Is Linked With Severity and Chronicity of Inflammation. Gastroenterology 150(Suppl 1), S575 
(2016).
 14. Johnson, L. A. et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a “Top-
Down” approach to intestinal fibrosis in mice. Inflammatory bowel diseases 18, 460–471, https://doi.org/10.1002/ibd.21812 (2012).
 15. Kradin, R. L. et al. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Experimental 
and molecular pathology 76, 205–211, https://doi.org/10.1016/j.yexmp.2003.12.010 (2004).
 16. Sakamoto, H., Zhao, L. H., Jain, F. & Kradin, R. IL-12p40(−/−) mice treated with intratracheal bleomycin exhibit decreased 
pulmonary inflammation and increased fibrosis. Experimental and molecular pathology 72, 1–9, https://doi.org/10.1006/
exmp.2001.2409 (2002).
 17. Zhu, J., Cohen, D. A., Goud, S. N. & Kaplan, A. M. Contribution of T lymphocytes to the development of bleomycin-induced 
pulmonary fibrosis. Annals of the New York Academy of Sciences 796, 194–202 (1996).
 18. Ng, T. H. et al. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 4, 129, https://doi.org/10.3389/
fimmu.2013.00129 (2013).
 19. Glocker, E. O., Kotlarz, D., Klein, C., Shah, N. & Grimbacher, B. IL-10 and IL-10 receptor defects in humans. Annals of the New York 
Academy of Sciences 1246, 102–107, https://doi.org/10.1111/j.1749-6632.2011.06339.x (2011).
 20. Chaudhry, A. et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. 
Immunity 34, 566–578, https://doi.org/10.1016/j.immuni.2011.03.018 (2011).
 21. Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3+ regulatory T cells in the human immune system. Nat Rev 
Immunol 10, 490–500, https://doi.org/10.1038/nri2785 (2010).
 22. Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. The New England journal of 
medicine 361, 2033–2045, https://doi.org/10.1056/NEJMoa0907206 (2009).
 23. Glocker, E. O. et al. Infant colitis–it’s in the genes. Lancet 376, 1272, https://doi.org/10.1016/s0140-6736(10)61008-2 (2010).
 24. Franke, A. et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nature 
genetics 40, 1319–1323, https://doi.org/10.1038/ng.221 (2008).
 25. van der Linde, K. et al. A Gly15Arg mutation in the interleukin-10 gene reduces secretion of interleukin-10 in Crohn disease. 
Scandinavian journal of gastroenterology 38, 611–617 (2003).
 26. Noguchi, E., Homma, Y., Kang, X., Netea, M. G. & Ma, X. A Crohn’s disease-associated NOD2 mutation suppresses transcription of 
human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nature immunology 10, 471–479, https://doi.
org/10.1038/ni.1722 (2009).
 27. Ra, H. J. & Parks, W. C. Control of matrix metalloproteinase catalytic activity. Matrix biology: journal of the International Society for 
Matrix Biology 26, 587–596, https://doi.org/10.1016/j.matbio.2007.07.001 (2007).
 28. Agrez, M. et al. The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. International journal of cancer 81, 
90–97 (1999).
 29. Agrez, M. V. et al. Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer. British journal of cancer 73, 
887–892 (1996).
 30. Goffin, L. et al. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease 
Complications with Fibrosis. Inflammatory bowel diseases 22, 2041–2057, https://doi.org/10.1097/MIB.0000000000000863 (2016).
 31. Obermeier, F. et al. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector 
molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 116, 238–245 (1999).
 32. Hausmann, M. et al. A new heterotopic transplant animal model of intestinal fibrosis. Inflammatory bowel diseases 19, 2302–2314, 
https://doi.org/10.1097/MIB.0b013e3182a6a0f3 (2013).
 33. Rittie, L. Method for Picrosirius Red-Polarization Detection of Collagen Fibers in Tissue Sections. Methods in molecular biology 
(Clifton, N.J.) 1627, 395–407, https://doi.org/10.1007/978-1-4939-7113-8_26 (2017).
 34. Rieder, F. & Fiocchi, C. Intestinal fibrosis in IBD–a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 6, 228–235, 
https://doi.org/10.1038/nrgastro.2009.31 (2009).
 35. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M. & O’Garra, A. IL-10 inhibits cytokine production by activated 
macrophages. Journal of immunology 147, 3815–3822 (1991).
 36. Bogdan, C., Vodovotz, Y. & Nathan, C. Macrophage deactivation by interleukin 10. The Journal of experimental medicine 174, 
1549–1555 (1991).
 37. Becherel, P. A. et al. Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human 
keratinocytes. European journal of immunology 25, 2992–2995, https://doi.org/10.1002/eji.1830251042 (1995).
 38. Seyler, I., Appel, M., Devissaguet, J. P., Legrand, P. & Barratt, G. Modulation of nitric oxide production in RAW 264.7 cells by 
transforming growth factor-beta and interleukin-10: differential effects on free and encapsulated immunomodulator. Journal of 
leukocyte biology 62, 374–380 (1997).
 39. Jarry, A., Bossard, C., Sarrabayrouse, G., Mosnier, J. F. & Laboisse, C. L. Loss of interleukin-10 or transforming growth factor beta 
signaling in the human colon initiates a T-helper 1 response via distinct pathways. Gastroenterology 141, 1887-1896.e1881-1882, 
doi:10.1053/j.gastro.2011.08.002 (2011).
 40. Lutz, C. et al. Myeloid differentiation primary response gene (MyD) 88 signalling is not essential for intestinal fibrosis development. 
Sci Rep 7, 17678, https://doi.org/10.1038/s41598-017-17755-7 (2017).
 41. Meier, R. et al. Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis. 
Inflammatory bowel diseases 22, 569–582, https://doi.org/10.1097/MIB.0000000000000716 (2016).
 42. Helene, M. et al. T cell independence of bleomycin-induced pulmonary fibrosis. Journal of leukocyte biology 65, 187–195 (1999).
 43. Jin, Y. et al. Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse 
model. Lab Invest 93, 801–811, https://doi.org/10.1038/labinvest.2013.64 (2013).
 44. Fang, Y., Sharp, G. C. & Braley-Mullen, H. Interleukin-10 promotes resolution of granulomatous experimental autoimmune 
thyroiditis. Am J Pathol 172, 1591–1602, https://doi.org/10.2353/ajpath.2008.071067 (2008).
 45. Demols, A. et al. Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am J Physiol 
Gastrointest Liver Physiol 282, G1105–1112, https://doi.org/10.1152/ajpgi.00431.2001 (2002).
 46. Mentink-Kane, M. M. et al. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and 
IL-13Ralpha2. Gastroenterology 141, 2200–2209, https://doi.org/10.1053/j.gastro.2011.08.008 (2011).
 47. Huang, Y. H. et al. Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats. World J Gastroenterol 12, 1386–1391 
(2006).
 48. D’Haens, G., Geboes, K. & Rutgeerts, P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. 
Gastrointestinal endoscopy 50, 667–671 (1999).
 49. Vermeire, S., van Assche, G. & Rutgeerts, P. Review article: Altering the natural history of Crohn’s disease–evidence for and against 
current therapies. Alimentary pharmacology & therapeutics 25, 3–12, https://doi.org/10.1111/j.1365-2036.2006.03134.x (2007).
 50. Solberg, I. C. et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clinical 
gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 5, 1430–1438, 
https://doi.org/10.1016/j.cgh.2007.09.002 (2007).
www.nature.com/scientificreports/
13SCIenTIFIC RePoRtS |  (2018) 8:15182  | DOI:10.1038/s41598-018-33452-5
Acknowledgements
This research was supported by grant IBD-0324R from the Broad Medical Research Foundation (BMRF) to MH. 
This research was also supported by grant No. 2013–16 from the Swiss inflammatory bowel disease cohort study 
(SIBDCS) to MH and by grant 314730_152895 from the Swiss National Science Foundation.
Author Contributions
C.L., A.H., S.F., P.A.R., B.W. and M.H. have nothing to disclose. G.R. discloses grant support from AbbVie, 
Ardeypharm, MSD, FALK, Flamentera, Novartis, Roche, Tillots, UCB and Zeller. MH discloses grant support 
from AbbVie and Novartis. H.A. acquisition, analysis and interpretation of data for Figures 7–10. F.S. acquisition, 
analysis and interpretation of data for Figures 7–10. R.G. study concept and design; critical revision of the 
manuscript for important intellectual content. L.C. acquisition, analysis and interpretation of data for Figures 
7–10; drafting of the manuscript. J.S.U. critical revision of the manuscript for important intellectual content. M.C. 
acquisition, analysis and interpretation of data for Figures 7–10; drafting of the manuscript. W.B. acquisition, 
analysis and interpretation of data for Figures 1–6; drafting of the manuscript. R.P.A. critical revision of the 
manuscript for important intellectual content. H.M. analysis and interpretation of data for Figures 1–10; study 
concept and design; drafting of the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-33452-5.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
